Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

103.04USD
1:27am IST
Price Change (% chg)

$0.41 (+0.40%)
Prev Close
$102.63
Open
$102.87
Day's High
$103.29
Day's Low
$102.21
Volume
1,503,677
Avg. Vol
2,141,644
52-wk High
$108.77
52-wk Low
$86.09

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products... (more)

Overall

Beta: 0.59
Market Cap (Mil.): $289,446.09
Shares Outstanding (Mil.): 2,820.29
Dividend: 0.70
Yield (%): 2.73

Financials

  JNJ.N Industry Sector
P/E (TTM): 17.01 33.08 33.86
EPS (TTM): 6.03 -- --
ROI: -- 18.26 17.52
ROE: -- 18.93 18.34
Search Stocks

NORDIC STOCKS - Factors to watch on Oct 24

OSLO, Oct 24 - The following stocks may be affected by newspaper reports and other factors on Friday:

24 Oct 2014

Johnson & Johnson's DePuy wins first trial over Pinnacle hips

NEW YORK/DALLAS - Johnson & Johnson was found not liable by a Texas jury on Thursday in the first case to go to trial over whether Pinnacle hip implants made by the company's DePuy Orthopedics unit were defective.

24 Oct 2014

UPDATE 2-Johnson & Johnson's DePuy wins first trial over Pinnacle hips

(Rewrites throughout, adds trial background and plaintiffs' lawyer quote, adds Dallas dateline)

24 Oct 2014

Johnson & Johnson's DePuy wins first trial over Pinnacle hips

NEW YORK, Oct 23 - Johnson & Johnson was found not liable by a Texas jury on Thursday in the first case to go to trial over whether Pinnacle hip implants made by the company's DePuy Orthopaedics unit were defective.

24 Oct 2014

Drugmakers to join forces to make millions of Ebola vaccine doses

LONDON - Leading drugmakers plan to work together to speed up the development of an Ebola vaccine and hope to produce millions of doses for use next year.

23 Oct 2014

Drugmakers to join forces to make millions of Ebola vaccine doses

LONDON - Leading drugmakers plan to work together to speed up the development of an Ebola vaccine and hope to produce millions of doses for use next year.

22 Oct 2014

J&J, GSK ready to collaborate on Ebola vaccine work

LONDON - Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson & Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration.

22 Oct 2014

J&J, GSK ready to collaborate on Ebola vaccine work

LONDON, Oct 22 - Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson & Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration.

22 Oct 2014

J&J and Bavarian Nordic expand production of an Ebola vaccine program

- Johnson & Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program.

22 Oct 2014

J&J and Bavarian Nordic expand production of an Ebola vaccine program

Oct 22 - Johnson & Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program.

22 Oct 2014

Earnings vs. Estimates

Search Stocks